TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06010303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: LBL-007 will be administered at a standard dose intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered at a standard dose intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab will be administered at a standard dose intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Doublet
Description: Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Doublet
Description: Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
Study: NCT05840003

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-Low-Dose thoraco-abdominopelvic scan
Description: In addition to the usual management (i.e. standard dose Computed Tomography), an Ultra-Low-Dose thoraco-abdominopelvic scan will be routinely performed.
Study: NCT06218420

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative and potentially efficient treatment of single or bilocular HCC. However, SBRT has not been validated as bridging therapy before LT in a prospective study yet.
Study: NCT05398250

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention tailored for Autistic Individuals
Description: To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts
Description: SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~1. A brief risk assessment and mood check~2. Review and, if needed, revision of SPI-A~3. Support related to outpatient mental health treatment initiation
Study: NCT06080243

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21/Matrix-M1
Description: 10 µg of R21 and 50 µg of Matrix-M1
Study: NCT06776744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: Eye Movement Desensitization and Reprocessing (EMDR) treatment. EMDR is one of the first-choice evidence based treatments for PTSD. During an EMDR session, the traumatic memory is brought to the surface including associated images, thoughts, feelings and body sensations, while simultaneously focusing on an external distracting stimulus (e.g., lateral eye movements).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: Eye Movement Desensitization and Reprocessing (EMDR) treatment. EMDR is one of the first-choice evidence based treatments for PTSD. During an EMDR session, the traumatic memory is brought to the surface including associated images, thoughts, feelings and body sensations, while simultaneously focusing on an external distracting stimulus (e.g., lateral eye movements).
Study: NCT06772519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: green colored lens glasses
Description: Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue colored lens glasses
Description: Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: colorless (transparent) lens glasses
Description: Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
Study: NCT06777160

Intervention type: PROCEDURE
Intervention: Collecting data from patients who underwent arthroplasty and cement was used
Description: Collecting data that may change in cement reaction before, during and after surgery from patients who underwent arthroplasty and cement use and taught it to artificial intelligence.
Study: NCT06776120

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal chemical test (FIT)
Description: Eligible participants will be instructed to collect their two stool samples within seven days prior to undergoing bowel preparation. These stool samples will be then submitted for a quantitative FIT (OC-SENSOR, EIKEN CHEMICAL, Japan). Colonoscopic observations and histopathological findings will be employed as the definitive reference standards for diagnosis.
Study: NCT06777394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: The HIIT program begins with a warm-up, followed by high-intensity repetitions separated by moderate-intensity recovery intervals. High-intensity exercises are performed near maximum effort, while moderate-intensity periods are maintained at 50% effort. HIIT exercises, involving low-skill movements in short bursts, enhance blood sugar regulation and fat-burning capacity.~The HIIT protocol has four phases:~Warm-Up: 10 minutes, gradually increasing to about 60% of maximum heart rate. Intervals: 4 minutes at 85-95% maximum heart rate. Relief/Recovery: 3 minutes at 60% maximum heart rate, repeated four times. Cool Down: 5 minutes, bringing the heart rate down to around 50% of maximum. Three key components determine the success of HIIT: intensity, duration, and recovery period. Exercises include dumbbell and kettlebell exercises, push-ups, squats, jump training, and stationary cycling

Intervention type: OTHER
Group type: OTHER
Intervention: Routine treatmet
Description: outine physical therapy includes stretching exercises, exercises to maintain a normal range of motion, and low-intensity and aerobic exercises for the patients.~Low-Intensity Exercise: The effects of low-intensity exercise become noticeable after about 20 minutes, providing a metabolic boost during the activity. Generally, a longer exercise duration further enhances metabolism.
Study: NCT06776926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Use of carbetocin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Use of carbetocin
Study: NCT04512560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training
Description: General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Training using Conventional Training Program
Description: General surgery residents (PGY 1-5) will continue their usual residency training.
Study: NCT06080243

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline and R21/Matrix-M1
Description: Saline and 10 µg of R21 and 50 µg of Matrix-M1
Study: NCT06363201

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin Oral solution
Description: Patients will receive one vial of Ocoxin® orally daily, preferably at the same time each day. The duration of treatment will depend on the chemotherapy schedule the patient will receive. Treatment with Ocoxin® will be from the start of oncospecific therapy until two weeks after the end of therapy.
Study: NCT06433349

Intervention type: OTHER
Intervention: Survey and interviews
Description: Questionnaires and interviews

Intervention type: OTHER
Intervention: Survey and interviews
Description: Questionnaires and interviews
Study: NCT04816188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy and Activity Modification
Description: Daily lower leg strengthening exercises Therapy and pain-guided activity modification.
Study: NCT05182398

Intervention type: OTHER
Intervention: Assesment
Description: Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
Study: NCT05935917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Description: 100 mg tablet of Form H and 100 mg tablet of Form II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Description: 100 mg tablet of Form H and 100 mg tablet of Form II
Study: NCT05526248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide(BAY1841788, Nubeqa)
Description: tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide(BAY1841788, Nubeqa)
Description: tablet, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: tablet, oral
Study: NCT06160999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Religious conferences
Description: The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine-in-a-van
Description: For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
Study: NCT06414889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim or biosimilar)
Description: Given by IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Given by procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given by IV
Study: NCT06333769

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course Radiotherapy
Description: Rectal lesion + metastatic lymph nodes, GTV 30Gy/5Fx. Pelvic lymphatic drainage area, CTV 22.5Gy/5Fx.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab：200mg，d1，q3w，2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine：1000mg/m2，d1-14，bid, q3w, 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin：130mg/m2, d1, q3w, 2 cycles
Study: NCT04696731

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-316
Description: ALLO-316 is an allogeneic CAR T cell therapy targeting CD70

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study: NCT06484855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 IV. Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 IV. Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 IV. Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355 placebo
Description: IBI355 placebo IV. Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355 placebo
Description: IBI355 placebo IV. Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355 placebo
Description: IBI355 placebo IV. Q4W
Study: NCT06169254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial current stimulation (tCS)
Description: Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial current stimulation (tCS)
Description: Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial current stimulation (tCS)
Description: Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
Study: NCT04879264

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-rating scale for severity of sleep disorders
Description: Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-rating scale for distress caused by sleep disorders
Description: Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
Study: NCT06186648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab + Obinutuzumab
Description: Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
Study: NCT05383248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Reward - High Variance
Description: Computerized reward learning task designed to increase reward responsiveness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Reward - Low Variance
Description: Computerized reward learning task designed to have minimal effect on reward responsiveness
Study: NCT05735587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-dried Blueberry Powder
Description: Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
Study: NCT05935345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addressing NSSI in schools
Description: During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.

Intervention type: OTHER
Group type: OTHER
Intervention: Control condition
Description: Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
Study: NCT06444880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by IV
Study: NCT05167734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Dextran
Description: 1000 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Description: 40,000 units subcutaneous
Study: NCT06465225

Intervention type: DEVICE
Intervention: Use of a powered alternating pressure air mattress
Description: Patients with a medium to high risk of developing pressure injury, without pressure injury, up during the day and lying between 15 and 20 hours per day will ly a on a R'GO Soins overlay mattress
Study: NCT06160804

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Skeletal traction
Description: A pin through the bone with weights attached

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral shaft splinting
Description: A splint of the broken thigh bone
Study: NCT05976828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBRX-042
Description: * Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBRX-042
Description: * Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBRX-042
Description: * Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose
Study: NCT06647030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURATE.DTx sessions
Description: Participants will interact with CURATE.DTx twelve minutes per day, three days a week, for ten weeks.~CURATE.DTx is a cognitive training DTx developed by our research team in The N.1 Institute for Health (N.1) and The Institute for Digital Medicine (WisDM). CURATE.DTx is comprised of CURATE.AI and a modified version of the Multi-Attribute Task Battery (MATB), Online MATB.~CURATE.AI is a small data AI-derived platform that can dynamically personalize treatment by modulating drug dose or therapy intensity. We previously implemented CURATE.AI into Online MATB - the modernized, online version of MATB, a flight deck simulator program developed by NASA and the United States Air Force.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: After the last DTx session (regardless of study completion by the participant), a 60-minute interview session will be conducted by a team member, either at the Institute for Digital Medicine (WisDM) in person or via Zoom. All responses will be audio-recorded and transcribed verbatim. We will use thematic analysis of anonymized transcripts to identify emerging or recurring themes. Data will be analyzed using NVivo. The analysis will begin with open/primary coding, where we will descriptively label data. Subsequently, we will group the labels into categories based on literature (i.e., secondary coding). These categories will then help create broader themes/assertions.
Study: NCT04899141

Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention
Description: stenting with the ihtDEStiny® sirolimus eluting stent
Study: NCT05567757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arteriovenous conduit implant
Description: Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
Study: NCT06252194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and doxycycline
Description: Metformin 500 mg tablet twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and doxycycline
Description: Metformin 500 mg tablet twice daily
Study: NCT05456828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG712
Description: ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
Study: NCT06272851

Intervention type: DEVICE
Intervention: optical coherence tomography
Description: measuring choroidal thickness using optical coherence tomography

Intervention type: DEVICE
Intervention: optical coherence tomography
Description: measuring choroidal thickness using optical coherence tomography
Study: NCT06401200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bar retained implant overdenture
Description: use of bar attachment in completely edentulous patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bar retained implant overdenture
Description: use of bar attachment in completely edentulous patient
Study: NCT06080243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile isotonic (0.9%) normal saline
Description: Saline
Study: NCT05460026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powerball Exercises
Description: Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
Study: NCT05977270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifebloom One
Description: LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
Study: NCT04905979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD113
Description: Two oral capsules administered before bed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Two oral capsules administered before bed